Cargando…

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

SIMPLE SUMMARY: Beyond mutations, epigenetic changes have been described as drivers for cancer as well. While leaving the overall DNA structure intact, they can be responsible for tumor malignancy by mediating the transcriptional upregulation of oncogenes. This provides the basis for “epigenetic the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jenke, Robert, Reßing, Nina, Hansen, Finn K., Aigner, Achim, Büch, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915831/ https://www.ncbi.nlm.nih.gov/pubmed/33562653 http://dx.doi.org/10.3390/cancers13040634

Ejemplares similares

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
por: Schäker‐Hübner, Linda, et al.
Publicado: (2022)

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy
por: Gutsch, Daniela, et al.
Publicado: (2021)

Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors
por: Goehringer, Nils, et al.
Publicado: (2021)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells
por: Jenke, Robert, et al.
Publicado: (2020)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

Therapeutic siRNA: State-of-the-Art and Future Perspectives
por: Friedrich, Maik, et al.
Publicado: (2022)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
por: Nakashima, Hiroshi, et al.
Publicado: (2015)

HDAC Inhibitors: Innovative Strategies for Their Design and Applications
por: Daśko, Mateusz, et al.
Publicado: (2022)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

Synthesis, Characterization and Biological Evaluation of Novel Dihydropyranoindoles Improving the Anticancer Effects of HDAC Inhibitors
por: Bingul, Murat, et al.
Publicado: (2020)

Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
por: Cross, Jasmine M., et al.
Publicado: (2020)

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
por: Cosenza, Maria, et al.
Publicado: (2018)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

Effects of novel HDAC inhibitors on urothelial carcinoma cells
por: Kaletsch, Aline, et al.
Publicado: (2018)

Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
por: Ye, Zi-Han, et al.
Publicado: (2023)

Prediction of individual response to anticancer therapy: historical and future perspectives
por: Unger, Florian T., et al.
Publicado: (2014)

HDAC inhibitors stimulate viral transcription by multiple mechanisms
por: Balakrishnan, Lata, et al.
Publicado: (2008)

HDAC inhibitors and cardioprotection: Homing in on a mechanism of action
por: Weeks, Kate L.
Publicado: (2019)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Synthesis and Evaluation of C15 Triene Urushiol Derivatives as Potential Anticancer Agents and HDAC2 Inhibitor
por: Qi, Zhiwen, et al.
Publicado: (2018)

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
por: Tu, Huang-Ju, et al.
Publicado: (2018)

Role of endoscopic ultrasound in anticancer therapy: Current evidence and future perspectives
por: Bratanic, Andre, et al.
Publicado: (2021)

Macrophage-Based Microrobots for Anticancer Therapy: Recent Progress and Future Perspectives
por: Nguyen, Van Du, et al.
Publicado: (2023)

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
por: von Bredow, Lukas, et al.
Publicado: (2022)

Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches
por: Li, Wenbo, et al.
Publicado: (2019)

HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
por: Karagiannis, Dimitris, et al.
Publicado: (2021)

HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells
por: Yar Saglam, Atiye Seda, et al.
Publicado: (2016)

Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
por: Tsai, Feng-Lung, et al.
Publicado: (2023)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Recent advances in epigenetic anticancer therapeutics and future perspectives
por: Ren, Liwen, et al.
Publicado: (2023)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres
por: Essien, Eno I., et al.
Publicado: (2022)

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
por: Fontana, Anna, et al.
Publicado: (2022)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019)

Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2022)

Correlation Analysis of Protein Expression of 10 HDAC/Sirtuin Isoenzymes with Sensitivities of 23 Anticancer Drugs in 17 Cancer Cell Lines and Potentiation of Drug Activity by Co-Treatment with HDAC Inhibitors
por: Behnisch-Cornwell, Steven, et al.
Publicado: (2021)

Graphene and graphene oxide with anticancer applications: Challenges and future perspectives
por: Shafiee, Ali, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_795t3vo5pjhmpad00bfgj295u7